Flavopiridol binds to duplex DNA

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2419-2428

  Bible, Keith C ^a,b   Bible Jr , Roy H ^c   Kottke, Timothy J ^a   Svingen, Phyllis A ^a   Xu, Kun ^b   Pang, Yuan Ping ^b   Hajdu, Elisabeth ^c   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; FLAVOPIRIDOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG DNA BINDING; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; APIGENIN; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIN-DEPENDENT KINASES; DNA; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; ETHIDIUM; FLAVONOIDS; FLUORESCENT DYES; HUMANS; IMMUNOBLOTTING; INTERCALATING AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PIPERIDINES; PYRAZOLES; RNA; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034194254     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Sedlacek, H. H., Czech, J., Naik, R., Kaut, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., and Sausville, E. Flavopiridol (L86 8275; NSC 649890): a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143-1168, 1996.
2. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16, 2986-2999, 1998.
3. Wright, J., Blatner, G. L., and Cheson, B. D. Clinical trials of flavopiridol. Oncology, 12: 1018-1024, 1998.
4. Czech, J., Hoffmann, D., Naik, R., and Sedlacek, H-H. Antitumoral activity of flavone L86-8275. Int. J. Oncol., 6: 31-36, 1995.
5. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
6. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E. A., and Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3: 273-279, 1997.
7. Bible, K. C., and Kaufmann, S. H. Flavopiridol (NSC 649890, L86-8275): a cytotoxic flavone that induces cell death in human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
8. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood, 92: 3804-3816, 1998.
9. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467-1472, 1997.
10. König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 90: 4307-4312, 1997.
11. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998.
12. Patel, V., Senderowicz, A. M., Pinto, D., Jr., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cyclin dependent kinase inhibitor, suppresses the growth of squamous cell carcinomas of the head and neck by inducing apoptosis. J. Clin. Invest., 102: 1674-1681, 1998.
13. Brüsselbach, S., Nettelbeck, D. M., Sedlacek, H-H., and Müller, R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int. J. Cancer, 77: 146-152, 1998.
14. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
15. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
16. de Azevedo, W. F., Mueller-Dieckmann, H-J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
17. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S. H., Lockhart, D. J., and Schultz, P. G. Exploiting chemical libraries, structures, and genomics in the search for kinase inhibitors. Science (Washington DC), 281: 533-538, 1998.
18. Drewinko, B., Patchen, M., Yang, L-Y., and Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res., 41: 2328-2333, 1981.
19. Boege, F., Straub, T., Kehr, A., Boesenberg, C., Christiansen, K., Andersen, A., Jakob, F., and Kohrle, J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J. Biol. Chem., 271: 2262-2270, 1996.
20. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
21. Adjei, A. A., Budihardjo, I., Rowinsky, E. K., Kottke, T. J., Svingen, P. A., Buckwalter, C. A., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin. Cancer Res., 3: 761-770, 1997.
22. Kaufmann, S. H., Svingen, P. A., Gore, S. D., Armstrong, D. K., Cheng, Y-C., and Rowinsky, E. K. Altered formation of topotecan-stabilized topoisomerase 1-DNA adducts in human leukemia cells. Blood, 89: 2098-2104, 1997.
23. Kohn, K. W. Principles, and practice of DNA filter elution. Pharmacol. Ther., 49: 55-77, 1991.
24. Martins, L. M., Mesner, P. W., Kottke, T. J., Basi, G. S., Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90: 4283-4296, 1997.
25. Adjei, A. A., Charron, M., Rowinsky, E. K., Svingen, P. A., Miller, J., Reid, J. C., Sebolt-Leopold, J., Ames, M. M., and Kaufmann, S. H. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II: prevention of cleavable complex formation. Clin. Cancer Res., 4: 683-691, 1998.
26. Karikas, G. A., Constantinou-Kokotou, V., and Kokotos, G. An HPLC method for the measurement of polyamines and lipidic amines binding DNA. J. Liq. Chromatogr. Relat. Technol., 20: 1789-1796, 1997.
27. Boyd, M. R., and Paull, K. D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34: 91-109, 1995.
28. Barone, V., and Cossi, M. Quantum calculation of molecular energies and energy gradients in solution by a conductor solvent model. J. Phys. Chem., 102: 1995-2001, 1998.
29. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84: 1736-1740, 1992.
30. Troelstra, C., van Gool, A., de Wit, J., Vermeulen, W., Bootsma, D., and Hoeijmakers, J. H. J. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell, 71: 939-953, 1992.
31. Horwitz, S. B., Chang, C. K., and Grollman, A. P. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. Mol. Pharmacol., 7: 632-644, 1971.
32. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
33. Hollingsworth, R. E., Jr., Hensey, C. E., and Lee, W. H. Retinoblastoma protein and the cell cycle. Curr. Opin. Genet. Dev., 3: 55-62, 1993.
34. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
35. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
36. Wilson, W. D., Barton, H. J., Tanious, F. A., Kong, S-B., and Strekowski, L. The interaction with DNA of unfused aromatic systems containing terminal piperazino substituents. Biophys. Chem., 35: 227-243, 1990.
37. Gabbay, E. J., and DePaolis, A. Topography of nucleic acid helices in solutions: steric requirements for interactions. J. Am. Chem. Soc., 93: 562-564, 1971.
38. Gabbay, E. J., Scofield, R. E., and Baxter, C. S. Steric effects on the intercalation of aromatic cations to deoxyribonucleic acid. J. Am. Chem. Soc., 95: 7850-7857, 1973.
39. Swenson, D. H., Li, L. H., Hurley, L. H., Rokem, J. S., Petzold, G. L., Dayton, B. D., Wallace, T. L., Lin, A. H., and Krueger, W. C. Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res., 42: 2821-2828, 1982.
40. 1H NMR. Proc. Natl. Acad. Sci. USA, 84: 2155-2159, 1987.
41. 31P NMR study of daunoruhicin-d(CGTACG) complex in solution: evidence of the intercalation sites. FEBS Lett., 236: 231-234, 1988.
42. 2: NMR evidence for multiple complexes. Biochemistry, 28: 5231-5239, 1989.
43. Ikemoto, N., Kumar, R. A., Ling, T-T., Ellestad, G. A., Danishefsky, S. J., and Patel, D. J. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc. Natl. Acad. Sci. USA, 92: 10506-10510, 1995.
44. Keniry, M. A., and Shafer, R. H. NMR studies of drug-DNA complexes. Methods Enzymol., 261: 575-603, 1995.
45. Spielmann, H. P., Wemmer, D. E., and Jacobsen, J. P. Solution structure of a DNA complex with the florescent bis-intercalator TOTO determined by NMR spectroscopy. Biochemistry, 34: 8542-8553, 1995.
46. Sebolt, J. S., Scavone, S. V., Pinter, C. D., Hemelehle, K. L., Von Hoff, D. D., and Jackson, R. C. Pyrazoloacridine, a new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res., 47: 4299-4304, 1987.
47. Reid, J. M., Walker, D. L., and Ames, M. M. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother. Pharmacol., 38: 329-334, 1996.
48. Liu, C., and Chen, F. M. Oligonucleotide studies of sequence-specific binding of chromomycin A3 to DNA. Biochemistry, 33: 1419-1424, 1994.
49. Brown, D. R., Kurz, M., Kearns, D. R., and Hsu, V. L. Formation of multiple complexes between actinomycin D and a DNA hairpin: structural characterization by multinuclear NMR. Biochemistry, 33: 651-664, 1994.
50. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol., 6: 393-397, 1996.
51. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
52. 2 arrest after DNA damage. Science (Washington DC), 282: 1497-1501, 1998.
53. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.